Evidence map›Paper›PMID 35117881›Full record

ArticleTranslational cancer research2020

Administration of amifostine in the stage of remission induction can benefit the patients with hematological malignancy in autologous stem cell transplantation: a retrospective study.

Min Wu, Kefei Wu, Pingping Chen, Pei Li, Yanhui Xie

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Min Wu *Department of Hematology, Huadong Hospital, Fudan University, Shanghai, China.
Kefei Wu *Department of Hematology and Oncology, Shanghai Children's Medical Center, Shanghai Jiao Tong University, Shanghai, China.
Pingping ChenDepartment of Hematology, Huadong Hospital, Fudan University, Shanghai, China.
Pei LiDepartment of Hematology, Huashan Hospital, Fudan University, Shanghai, China.
Yanhui XieDepartment of Hematology, Huadong Hospital, Fudan University, Shanghai, China.
Fudan University · CNHuadong Hospital · CNShanghai Jiao Tong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo investigate whether the administration of amifostine in the stage of remission induction can benefit patients with hematological malignancy in autologous stem cell transplantation (ASCT).

methodsTwo historical groups of patients who received prophylactic amifostine in the stage of remission induction and ASCT (group A, n=95) or amifostine in ASCT only (group B, n=73) were included. The chemotherapy-associated side effects in peripheral blood stem cell (PBSC) mobilization, total average monocyte per kilogram in stem cells collections, hematologic toxicity and engraftment kinetics, non-hematologic toxicity, therapeutic response after ASCT were compared between the two groups.

resultsFor PBSCs mobilization, the rate of fever in group A was significantly higher (24/95

conclusionsProphylactic amifostine can reduce mucositis, improve monocytes collection and promote hematopoietic recovery in ASCT.

Indexed as

Amifostineautologous stem cell transplantation (ASCT)hematological malignancyremission induction

Identifiers

PMID35117881
PMCPMC8798436
OpenAlexW3086393364

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.